These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 16377674)

  • 1. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
    Aubry A; Veziris N; Cambau E; Truffot-Pernot C; Jarlier V; Fisher LM
    Antimicrob Agents Chemother; 2006 Jan; 50(1):104-12. PubMed ID: 16377674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
    Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
    Matrat S; Veziris N; Mayer C; Jarlier V; Truffot-Pernot C; Camuset J; Bouvet E; Cambau E; Aubry A
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4170-3. PubMed ID: 17015625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
    Zhu C; Zhang Y; Shen Y; Siu GK; Wu W; Qian X; Deng G; Xu Y; Lau R; Fan X; Zhang W; Lu H; Yam WC
    Diagn Microbiol Infect Dis; 2012 Jul; 73(3):260-3. PubMed ID: 22560167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
    Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
    Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.
    Pantel A; Petrella S; Veziris N; Brossier F; Bastian S; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1990-6. PubMed ID: 22290942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA; Warren RM; Streicher EM; Victor TC; van Helden PD; Böttger EC
    J Antimicrob Chemother; 2012 May; 67(5):1088-93. PubMed ID: 22357804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Veziris N; Matrat S; Bouige A; Ferrand H; Sougakoff W; Mayer C; Aubry A
    J Antimicrob Chemother; 2016 Sep; 71(9):2428-31. PubMed ID: 27234461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand.
    Pitaksajjakul P; Worakhunpiset S; Chaiprasert A; Boonyasopun J; Ramasoota P
    Southeast Asian J Trop Med Public Health; 2011 Sep; 42(5):1163-7. PubMed ID: 22299442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China.
    Chen J; Chen Z; Li Y; Xia W; Chen X; Chen T; Zhou L; Xu B; Xu S
    Braz J Infect Dis; 2012; 16(2):136-41. PubMed ID: 22552454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China.
    Long Q; Li W; Du Q; Fu Y; Liang Q; Huang H; Xie J
    Int J Antimicrob Agents; 2012 Jun; 39(6):486-9. PubMed ID: 22526012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
    Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
    J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates.
    Sun Z; Zhang J; Zhang X; Wang S; Zhang Y; Li C
    Int J Antimicrob Agents; 2008 Feb; 31(2):115-21. PubMed ID: 18164184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance.
    Kim H; Nakajima C; Yokoyama K; Rahim Z; Kim YU; Oguri H; Suzuki Y
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3661-7. PubMed ID: 21646485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
    Singh P; Jain A; Dixit P; Prakash S; Jaiswal I; Venkatesh V; Singh M
    J Antibiot (Tokyo); 2015 Jan; 68(1):63-6. PubMed ID: 25052485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009.
    Cui Z; Wang J; Lu J; Huang X; Hu Z
    BMC Infect Dis; 2011 Mar; 11():78. PubMed ID: 21443804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.